Frontiers Production Office
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
by Li D, Lin Y, Lv X, Wu Y, Han C, Cao P, Zhang G, Leng A, Zhou J and Wang C (2024). Front. Pharmacol. 15:1485209. doi: 10.3389/fphar.2024.1485209
Due to a production error, the funders “National Natural Science Foundation of China (82374297), Dalian Science and Technology Leading Talents Project (2020RJ09), Dalian Science and Technology Innovation Fund (2023JJ12SN033)” to “Chao Wang”; and “Dalian Medical University Intensified Program of Wellness Interdisciplinary Research Cooperation Project Team Funding (JCHZ2023004)” to “Guixin Zhang” were erroneously removed. The corrected Funding statement is below:
Funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. CW: National Natural Science Foundation of China (82374297), Dalian Science and Technology Leading Talents Project (2020RJ09), Dalian Science and Technology Innovation Fund (2023JJ12SN033). JZ: The Natural Science Foundation for Academic and Technical Leaders of Jiangxi Province (grant number 20212BCJ23026), 2023 National Training Program for Inheritance of Characteristic Techniques of Traditional Chinese Medicine (T20234832005), the Traditional Chinese Medicine Key Laboratory of Jiangxi Province (KP202203007), Traditional Chinese Medicine Science and Technology Plan of Jiangxi Provincial Health and Family Planning Commission (No. 2023B1319). GZ: Dalian Medical University Intensified Program of Wellness Interdisciplinary Research Cooperation Project Team Funding (JCHZ2023004).
The publisher apologizes for this mistake. The original article has been updated.
Keywords: Ganoderma lucidum, functional food, CYP450s, lanostrane triterpenoid, drug-drug interactions
Citation: Frontiers Production Office (2024) Erratum: Triterpenoids from Ganoderma lucidum inhibit cytochrome P450 enzymes interfering with the metabolic process of specific clinical drugs. Front. Pharmacol. 15:1539089. doi: 10.3389/fphar.2024.1539089
Received: 03 December 2024; Accepted: 03 December 2024;
Published: 19 December 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn